Guggenheim maintains Buy on Travere Therapeutics, raises target to $65
Guggenheim analyst Vamil Divan maintained a Buy rating on Travere Therapeutics (NASDAQ: TVTX) and raised the price target to $65 from $56, following a similar move by Wedbush which set a target of $61.
*this image is generated using AI for illustrative purposes only.
Guggenheim analyst Vamil Divan has maintained a Buy rating on Travere Therapeutics (NASDAQ: TVTX) while raising the stock's price target to $65 from $56. The adjustment reflects an updated valuation outlook for the biopharmaceutical company. Wedbush analyst Laura Chico also recently maintained an Outperform rating on the stock, raising the target to $61 from $55.
The revised targets suggest potential upside from current trading levels, reinforcing the positive stance on the company's prospects. Travere Therapeutics focuses on the development and commercialization of therapies for rare diseases.
| Firm | Rating | Previous Target | New Target |
|---|---|---|---|
| Guggenheim | Buy | $56 | $65 |
| Wedbush | Outperform | $55 | $61 |
Both firms cite the company's continued progress in its therapeutic pipeline as a key driver for the revised outlook.
What specific pipeline milestones are expected to drive the most value for Travere Therapeutics in the coming year?
How might the competitive landscape for rare disease therapies impact Travere's ability to meet these revised price targets?
What are the potential regulatory hurdles that could affect the commercialization of Travere's key therapies?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
